GlassScriptPhysician profile
Steven D Buchan
NPI 1891880571
$4,122.96
in general payments reported to CMS, 2019-2025
34 companies · $742 in 2025
The $742 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $339 · 2021: $759 · 2022: $504 · 2023: $834 · 2024: $561 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,136.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $412.77 | 2019-2024 | |
| Pfizer INC. | $361.83 | 2019-2025 | |
| Amarin Pharma, INC. | $360.17 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $339.66 | 2020-2025 | Airsupra, Fasenra |
| Idorsia Pharmaceuticals US INC | $336.39 | 2022-2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $333.91 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $283.15 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $242.11 | 2021-2025 | Verquvo, Belsomra |
| Esperion Therapeutics, INC. | $152.13 | 2021-2024 | Nexletol |
| Glaxosmithkline, LLC. | $148.65 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $125.79 | 2021-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $123.11 | 2022-2023 | Xarelto |
| Amgen INC. | $112.54 | 2019-2025 | Evenity, Prolia, Repatha |
| E.R. Squibb & Sons, L.L.C. | $111.42 | 2021-2025 | Eliquis, Camzyos |
| Exact Sciences Corporation | $107.78 | 2023-2025 | Cologuard Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $88.01 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Teva Pharmaceuticals USA, INC. | $75.96 | 2019 | |
| Abbott Laboratories | $50.68 | 2021-2025 | Freestyle Libre 3 |
| Chiesi USA, INC. | $41.77 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $41.37 | 2024-2025 | Opsumit, Uptravi |
| Inspire Medical Systems, INC. | $32.47 | 2025 | Inspire |
| Allergan, INC. | $29.84 | 2019 | |
| Dexcom, INC. | $24.16 | 2024 | Dexcom G6 Transmitter |
| Mayne Pharma Commercial LLC | $23.53 | 2023 | |
| Vivaquant INC, Dba Rhythm Express | $22.00 | 2025 | Rhythm Express |
| Lexicon Pharmaceuticals, INC. | $21.33 | 2023 | Inpefa |
| Sanofi Pasteur INC. | $20.92 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.08 | 2021 | |
| Baxter Healthcare | $15.71 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Abiomed | $15.71 | 2024 | Impella |
| Abbvie INC. | $15.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.80 | 2021 | |
| Genentech USA, INC. | $12.17 | 2019 | |
| Dynavax Technologies Corporation | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Buchan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.